Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Khanna, Sahil; Assi, Maha; Lee, Christine; Yoho, David; Louie, Thomas; Knapple, Whitfield L.; Aguilar, Humberto; Garcia‐Diaz, Julia; Wang, Gary P.; Berry, Scott M.; Marion, Joe; Su, Xin; Braun, Tricia; Bancke, Lindy; Feuerstadt, Paul

doi:10.1007/s40265-022-01805-0

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent approval of Rebyota as a new drug by the FDA was based on the allogenic healthy fecal matter. [188] An intriguing idea proposed by Ke et al suggests the creation of a personal microbial Noah's ark using stool banks to collect hosts' stool samples at optimal health and cryopreserve them for future autologous transplantation. [189] This approach may increase the safety of transplanting bacteria or the virome in future practice.…”

Section: Allogenic or Autologous Transplantationmentioning

confidence: 99%

The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome

Yu,

Wang,

Zhang

2023

Advanced Science

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic approach for dysbiosis‐related diseases. However, the clinical practice of crude fecal transplants presents limitations in terms of acceptability and reproductivity. Consequently, two alternative solutions to FMT are developed: transplanting bacteria communities or virome. Advanced methods for transplanting bacteria mainly include washed microbiota transplantation and bacteria spores treatment. Transplanting the virome is also explored, with the development of fecal virome transplantation, which involves filtering the virome from feces. These approaches provide more palatable options for patients and healthcare providers while minimizing research heterogeneity. In general, the evolution of the next generation of FMT in global trends is fecal microbiota components transplantation which mainly focuses on transplanting bacteria or virome.

show abstract

Section: Allogenic or Autologous Transplantationmentioning

confidence: 99%

The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome

Yu,

Wang,

Zhang

2023

Advanced Science

View full text Add to dashboard Cite

show abstract

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy

Dureja,

Rutherford,

Pavel

et al. 2024

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stems from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical trial results for recent antibiotic candidates, underscores the urgent need for novel CDI antibiotics. To this end, we investigated C. difficile enoyl ACP reductase ( Cd FabK), a crucial enzyme in de novo fatty acid synthesis, as a drug target for microbiome-sparing antibiotics. To test this concept, we evaluated the efficacy and in vivo spectrum of activity of the phenylimidazole analog 296, which is validated to inhibit intracellular Cd FabK. Against major CDI-associated ribotypes 296 had an Minimum inhibitory concentration (MIC 90 ) of 2 µg/mL, which was comparable to vancomycin (1 µg/mL), a standard of care antibiotic. In addition, 296 achieved high colonic concentrations and displayed dosed-dependent efficacy in mice with colitis CDI. Mice that were given 296 retained colonization resistance to C. difficile and had microbiomes that resembled the untreated mice. Conversely, both vancomycin and fidaxomicin induced significant changes to mice microbiomes, in a manner consistent with prior reports. Cd FabK, therefore, represents a potential target for microbiome-sparing CDI antibiotics, with phenylimidazoles providing a good chemical starting point for designing such agents.

show abstract

Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Cited by 2 publications

References 0 publications

The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome

The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy

Contact Info

Product

Resources

About